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INTRODUCTION 
CRP is secreted  as a acute phase reactant that is primarily 
produced in the liver in response to elevations of cytokines in the  
blood, like IL-6 and TNF-alpha. 
The developing atherosclerotic lesion is of a inflammatory nature  
which provides a link between production of activating cytokines in the 
atheroma and the generation of CRP which is hepatically produced. 
Evidence suggests that CRP may play a direct role in worsening 
atherosclerosis and raising the risk of cardiovascular events . 
A large ammount of epidemiologic evidence supports CRP as 
an independent prognostic indicator of  future CV events 
irrespective of male or female. CRP has also been used as a 
prognostic indicator in patients with both acute coronary syndromes 
and stable, chronic coronary disease. 
In the landmark JUPITER study of healthy 
normocholesterolemic persons (LDL cholesterol <130 mg/dL)  and 
higher levels of highly sensitive CRP >2.0 mg/L), treatment with a 
potent statin  that lowers CRP caused a reduction in CV events 2 
times that which would be expected from the reduction in LDL 
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cholesterol alone. Similar results have been found in studies of 
statin therapy in patients with coronary disease. 
 Those with the greatest CRP reductions have the best 
cardiovascular outcomes, independent lowering of LDL.  
The mechanisms by which hypertension increases the risks of 
ischemic coronary events may include impairment of endothelial 
function, increased oxidative stress, increased endothelial lipid 
permeability, as well as hemodynamic stress. Randomized trials 
have demonstrated that lowering blood pressure (BP) can rapidly 
reduce cardiovascular risk, with a sustained drop of 10mm Hg 
leading up to a 40-50% reduction in risk. 
Treatment of elevated lipid levels reduces cardiovascular morbidity 
and mortality,improving quality of life and extending life expectancy.  
The comprehensive cardiovascular risk assessment for 
patients with a lipid disorder begins with  measuring lipid levels 
and those identified by the Framingham Risk Score. These include 
hypertension, smoking, diabetes, family history of premature CAD, 
age, sex, and presence of established CAD or other atherosclerotic 
disease (e.g.,peripheral arterial insufficiency, symptomatic carotid 
disease). 
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AIM AND OBJECTIVES 
 To evaluate HsCRP levels and correlate it with the lipid 
profile in hypertension. 
 To correlate the above biochemical parameters in identifying 
patients who  are at higher risk of developing coronary artery 
disease (CAD) and for providing primary prevention 
treatment in such patients. 
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REVEIW OF LITERATURE 
HIGHLY SENSITIVE C REACTIVE PROTEIN (HSCRP) 
INTRODUCTION 
Highly Sensitive C Reactive Protein (hsCRP) known as ultra 
sensitive CRP also called as cardiac CRP. It measures low levels of 
CRP using nephelometry or immuno turbidimetry technique. Since 
the method has high sensitivity, even small quantity (1–10 ng/dL) 
can be measured accurately. 
CRP levels increase in the blood with  onset of inflammation. 
Even a low level of persistent inflammation contributes  to a 
important role in  development of atherosclerosis. 
The High sensitivity CRP (hs CRP) test measures accurately 
very  low levels of CRP and detects very low levels of 
inflammation which in turn  can predict a individual's risk of 
developing CAD. 
Highly sensitive CRP is a useful test for determining risk of 
.It is a marker of at  risk for atherosclerosis process and is used as a 
predictor for future myocardial infarction within the next 120 
months. More than fifty percent of cardiovascular events and CVAs 
happen in those who do not have dyslipidemia, measuring  hsCRP  
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levels can help to identify patients who are at risk and  may need 
primary preventive treatment. 
 
The hs CRP test clearly adds to the predictive value. The best 
method to predict risk  of CAD is to combine a surrogate and 
sensitive marker of inflammation, like hsCRP, with the lipid levels.  
HISTORY 
CRP was first described by Tillet and Francis in 930.  
Experiments revealed serum of patients suffering from acute 
bacterial infection showed precipitation with the C polysaccharide 
pneumococcus extract. This reaction causing  protein was  called C-
reactive protein (CRP).  
The discovery of CRP  was in the sera of a patient 
with pneumonia caused by S. pneumonia infection. CRP was 
present in very high concentrations in  the acute phase sera of the 
patient  and caused precipitation of pneumococcal cell wall extracts 
but only in the presence of calcium ions. 
Most of the  acute inflammatory processes and some 
malignancies, cause a  rise in CRPlevels  as a non specific 
mechanism.  
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STRUCTURE OF CRP 
CRP has a unique pentraxin configuration,. In humans one of 
the  two members of this family are CRP . 
 
Structure of C-reactive protein (CRP),Pentraxin model 
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Structure of CRP 
 
COMPARISON OF THE PROPERTIES BETWEEN CRP AND 
SERUM AMYLOID P (SAP) 
Production  of CRP in hepatocytes is mediated  by cytokines. 
Interleukins 1, 6 and TNF .The CRP molecule is arranged in a 
doughnut shaped polymer. 
PATHOPHYSIOLOGY OF CRP 
Genes for  CRP lie on chromosome 1q23.2 in man .CRP is 
secreted as an acute phase reactant protein.It has a plasma half life 
of 19 hours,it also functions as opsonins for pathogenic bacterial 
micro organisms  through activation of the complement pathway 
and through binding to Fc gamma receptors.  
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CRP complexes 
CRP is produced in the liver and in the smooth muscle cells 
of an atherosclerotic plaque.Among the various markers, significant 
importance has been given to circulating levels of CRP as a risk 
indicator.  
The CRP levels in blood can be measured accurately and 
reproducible to very low levels by latest advanced high sensitivity 
assays. It is a stable molecule with a long half life of 19 hours 
approximately and does not show circadian variation.                                
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The general population  have stable CRP levels characteristic 
for each individual except occasional increases associated with 
minor or subclinical infections, trauma, or inflammation. The levels 
of CRP may also be regulated by genetic variations.  
Twin studies show a highly significant genetic basis for CRP 
levels which is independent of age and body mass index. 
C-REACTIVE PROTEIN AND PATHOGENESIS OF 
ATHEROTHROMBOSIS 
It has been demonstrated that  cellular effects of CRP may 
directly cause atherothrombosis thus acting as a risk factor in 
addition to being a risk marker. Recent datas show that CRP may  
also be produced by vascular wall cells where it has  
proinflammatory effects and stimulate macrophage uptake of LDL, 
thereby contributing to the pathogenesis of atherothrombosis.  
CRP which is immunoreactive has been identified in 
atheromatous plaques. aggregated  fraction of CRP binds to LDL, 
whereas native fraction CRP binds to oxidized and aggregated LDL  
which leads to complement activation . Complement 
activation,experimentally has shown to be  involved in 
atherogenesis, could  be one significant mechanism by which CRP 
could contribute to atherogenesis. 
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Recent datas, have changed the view that the liver exclusively 
produces CRP where transcriptional PCR data suggest that 
endothelial cells ,smooth muscle cells and macrophages are also 
capable of producing CRP.  
Other than cells themselves, CRP is also produced in 
atherosclerotic plaques where, according to many independent 
studies, it is involved in atherothrombosis and plaque vulnerability 
by mediating the secretion of  vascular adhesion molecules, 
inducing production of NO, alteration of innate complement 
functions, uptake of oxidized LDL, matrix degradation, and 
inhibition of intrinsic fibrinolysis. 
CRP directly involves in the atherosclerotic process initiating 
the innate inflammatory response, stopping production of 
endothelial nitric oxide synthase, by activation of PAI-1,  all of 
which have a direct effect on arterial thrombosis.  
The free radicals oxidize PUFA present in LDL,this modified 
LDL is not recognized by the hepatocytes in liver, so it is taken up 
by macrophage scavenger receptors present on macrophages 
resulting in formation of foam cells, thus starting the 
atherosclerotic process . 
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The exact mechanisms of CRP elevation in vascular disease 
are not well understood and several mechanisms have been 
proposed Amplified release of cytokines IL-1and IL-6 from 
inflammatory focus within  the atherosclerotic plaque leading to 
hepatic overproduction of CRP.  
Intimal smooth muscle myocyte damage from acute vascular 
occlusion causing an acute phase response.  
Systemic stimuli that cause chronic inflammation leading to 
increased CRP levels and endovascular inflammation. 
CRP and Vascular Disease risk in subjects without any known 
vascular disease or with subclinical vascular disease. 
Several prospective trails have shown that, individuals 
without any underlying cardiovascular disease or known preclinical 
vascular disease, elevated CRP levels measured by high sensitivity 
assays, are associated with an increased future risk of 
cardiovascular events. 
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CRP LEVEL  AND THE FRAMINGHAM SCORE 
 
22 studies on CAD risk and CRP levels 
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Elevated CRP levels have also been noted with obesity, type 
2 diabetes, insulin resistance. Elevated CRP and IL-6 levels are 
shown to predict an increased risk of future development of type 2 
diabetes in the Women’s Health Study .  
 
Diagram shows the steps in disease progression for acute 
coronary syndrome and the associated increases in serum biomarker 
levels 
An European prospective trial on more than two thousand patients 
with, elevated levels  of CRP and angina were at an increased risk for 
future myocardial infarction or sudden cardiac death . 
CRP LEVELS AND RISK OF CARDIOVASCULAR DISEASES  
 Many studies in ACS have shown that elevated CRP levels are 
associated with increased risk of cardiovascular complications 
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including cardiac rupture and that successful reperfusion is associated 
with a fall in elevated CRP levels beyond that predictable on the basis 
of infarct size reduction . 
CRP AND THERAPEUTIC INTERVENTIONS 
CRP levels are elevated in presence of risk factors like 
obesity, insulin resistance, and smoking, importance  on risk 
modification is needed in such cases to reduce the pro 
cardiovascular risk  and inflammatory state .  
Increased cardiovascular risk associated with elevated levels 
of CRP in healthy individuals was shown to be neutralised by use 
of aspirin in one study . The group in the lowest quartile of risk had 
only a 15% RRR, whereas the group in the highest quartile of risk 
experienced a robust 55% RRR with aspirin.  
Many studies have shown that CRP levels fall with starting of  
statin therapy, often independent of LDL lowering, reflecting their 
anti inflammatory  and pleiotropic effects . Some of the studies have 
showed that the decrease in CRP with statins occurs independent of 
LDL lowering. 
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Additional studies are needed to definitively prove whether 
CRP lowering is or is not related to lipid (both LDL and non LDL 
lipid fractions) modifying effects of statins.  
Also data from the CARES secondary prevention trial showed 
that pravastatin was most effective in reducing cardiovascular risk 
in the group with elevated CRP levels . Retrospective analysis of 
the AFCAPS/TEXCAPS primary prevention trial also showed that 
increased cardiovascular risk associated with elevated CRP levels 
was reduced by statin therapy (lovastatin), even in subjects with 
average or below average cholesterol levels . 
It has also been shown that CRP has an additive value across all 
levels of lipid screening, even after adjustment for age, smoking, blood 
pressure, obesity, and diabetes.hsCRP from sudden cardiac death victims 
showed a positive correlation with its recognition by immunostaining of 
plaques and as a predictor of high risk thin cap fibroatheromas. 
Accumulated CRP was localized mainly to the necrotic core 
and surrounding macrophages where its strongest expression was 
found in patients with high serum CRP levels. The clinical use of 
CRP significantly added to the predictive value of total and HDL 
cholesterol.                         
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CRP AS RISK FACTOR  OF CARDIOVASCULAR EVENTS 
Studies show that inflammation is linked with atherosclerosis, 
and low levels of CRP may be an indicator of atherosclerosis. 
Myocardial infarction is due to as a result of inflammation 
mediated atherosclerosis. This inflammation has a role in 
pathogenesis of cardiovascular events. 
Around 50% of all myocardial infarctions happen in 
individuals who do not have dyslipidemia. The inclusion of 
measuring of CRP levels to the screening tests based on lipid levels 
can provide an improvised method of identifying women who are  
at risk of  developing cardiovascular events.  
Endothelial damage resultsdue to inflammation . CRP is 
marker for inflammation  and it can be a surrogate marker for CAD 
risk.  
The AHAssociation  has classified risk groups as follows  
 Low Risk with HsCRP less than 1.0 mg/L 
 Average risk with HsCRP between 1.0 to 3.0 mg/L 
 High risk with HsCRP more3.0 mg/L 
hsCRP  should not be used alone and can be combined with 
dyslipidemia, and blood glucose levels. 
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An elevated serum CRP is a predictor of the development and 
progression of atherosclerosis, of future coronary events including 
unstable angina pectoris and acute myocardial infarction.Serum CRP 
levels correlate well as a predictor of cardiovascular events than is LDL- 
cholesterol.  
VARIOUS CARDIOVASCULAR RISK PREDICTION TOOLS 
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RECOMMENDATIONS OF ACC/AHA FOR THE 
MEASUREMENT OF CRP 
INTERVENTIONS THAT LOWER CRP 
At present  no specific therapies are  available to lower CRP 
levels reduction  
Lifestyle modification, weight loss, and stopping smoking 
have beneficial effects on proinflammatory markers, including 
CRP. Several drugs such as peroxisome proliferator activated 
receptors agonists , ACE inhibitors, ARBs, aspirin , niacin 
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,clopidogrel , and statins  have also been shown to decrease serum 
CRP levels. 
CLINICAL SIGNIFICANCE OF CRP LEVELS REDUCTION 
Eventhough  CRP has been studied as an independent 
predictor for future CV events in asymptomatic individuals,most of 
the epidemiologic studies report only the relative risk and fail to 
show the absolute risk associated with increased CRP or the 
receiver operating curve comparing CRP to other 
risk factors, making it difficult to gauge the true incremental 
value of using CRP for cardiovascular risk prediction. 
The factors that reduce serum CRP levels and cause a 
reduction in the incidence of cardiovascular events. These 
include the following: 
 Exercise; Diet high in fiber soy and nuts; Quiting Smoking; 
HMG-CoA reductase inhibitors; Beta adrenergic blockers and 
Ezetimibe a cholesterol lowering agent. 
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HYPERTENSION 
DEFINITION.  
Hypertension is defined by a  sustained SBP ≥140 mmHg or a 
DBP ≥90 mmHg.  
A single recording  of elevated BP may be enough if systolic 
or diastolic blood pressures are significantly elevated, if symptoms 
are present, but  very high fluctuations in blood pressure above 
base line BP in a healthy individual may occur transiently during 
acute illness or extreme physical and emotional stress . 
 Blood pressure ≥135/85 mmHg outside the doctor’s office 
also could be considered elevated.The term prehypertension has 
been designated for BP 120–139 mmHg systolic or 80–89 diastolic. 
Patients with prehypertension are targets for lifestyle modifications 
that can prevent or delay the onset of hypertension. 
Blood pressure (BP) has a continuous,normal bell shaped 
(Gaussian) distribution. 
Hypertension is the most common cardiovascular disease.The 
natural course of untreated hypertension increases the risk of fatal 
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and nonfatal coronary artery disease, congestive heart failure, 
stroke,acute and chronic kidney disease and all cause mortality.  
 Depending on the level of hypertension, age, gender,other 
risk factors for target organ damage ,atherosclerosis and 
cardiovascular disease, the 10 year risk t varies from less than 15 % 
to more than 40%. Epidemiological studies indicate that > 60% of 
CV events happen in persons with high or moderate hypertension 
and who have other risk factors such as dyslipidaemia, glucose 
intolerance or coronary artery disease. 
More than 85% of hypertension is idiopathic, while 10%–15% 
can be due to identifiable causes (secondary hypertension).  
Essential hypertension is usually idiopathic, and 
inappropriate secondary retention of salt and water. Over long 
periods, this leads to accelerated atherosclerosis in arteries causing 
increased workload and hypertrophy of the heart.  
APPROACH TO DIAGNOSIS AND TREATMENT OF 
PATIENTS WITH HTN 
1) First confirm the diagnosis of hypertension.  
2) Evaluate clinically for other cardiovascular risk factors, target 
organ damage, secondary hypertension and cardiovascular disease. 
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3) Initiate therapy depending on the severity of the hypertension 
and other comorbid risks 
 
CLASSIFICATION OF HYPERTENSION ON THE BASIS OF 
BLOOD PRESSURE 
Regulation of Blood Pressure 
BP is the product of peripheral vascular resistance and 
cardiac output ,given by the equation: BP = CO × PVR. 
 
Anatomic sites of blood pressure control 
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Appropriate diagnosis and management of hypertension 
require accurate and representative BP measurement. There is 
commonly a physiologic 15% to 20% variation in hour to hour BP 
readings. Studies using ambulatory BP monitoring 
(ABPM ) reveal BP is generally highest during the day, 
lowest during sleep, and increases during the period from 4:00 am 
to 12:00 pm, correlating with diurnal cortisol levels .  
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CARDIOVASCULAR RISK FACTORS AND TARGET-
ORGAN DAMAGE (JNC-VII, 2003) 
APPROACH TO  A PATIENT WITH HTN 
Investigate for damageto  target organs and evidence of 
atherosclerotic disease, looking for evidence of cardiomegaly or 
heart failure, vascular insufficiency, bruits, and possible signs of 
secondary hypertension such as thyromegaly.  Look for 
comorbidities such as diabetes or renal dysfunction, and calculating 
body mass index for cardiac risk stratification.Routine fundoscopy  
USEFUL INITIAL TESTS FOR PATIENTS WITH 
HYPERTENSION  
1) Total cholesterol,High density lipoprotein. 
2) Serum potassium,sodium, creatinine (calculate glomerular 
filtration rate and screen for secondary causes). 
3) (3)A resting electrocardiogram may show left ventricular 
hypertrophy, presence of coronary artery disease, and 
conduction blocks, important when using antihypertensive 
medications that have nodal blocking activity.  
4) (4)Urinalysis (screen for proteinuria) 
5) (5)Fasting glucose, or HBA1c (glycosylated hemoglobin).  
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PATHOPHYSIOLOGY OF HYPERTENSION 
Hypertension is usually associated with other cardiovascular 
risk factors, including diabetes mellitus, hyperinsulinemia, 
dyslipidemia, and obesity . In combination, these risk factors are 
synergistic rather than merely additive.  
Obesity causes a six fold increase in the probability of 
developing hypertension and accounts for 68% to 80% of its 
attributable risk .  
Among patients with concomitant hypertension and 
dyslipidemia, coronary artery disease prevalence more than doubles 
compared with those with either condition alone . Smoking and 
alcohol use also contribute to cardiovascular morbidity.  
 
Factors involved in the pathogenesis of hypertension 
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Cigarette smoking leads to endothelial damage and 
atherosclerosis. Consuming three or more alcoholic drinks a day 
increases BP, even when controlling for body mass index, cigarette 
smoking, and age. 
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SECONDARY HYPERTENSION  
PRINCIPLES OF MANAGEMENT 
Goal of Antihypertensive Therapy 
Antihypertensive therapy is aimed at preventing 
cardiovascular morbidity and mortality. Nonpharmacologic lifestyle 
and diet changes are essential for all patients.  
Drug therapy for those with hypertension and those with 
prehypertension who have compelling indications, such as chronic 
kidney disease or diabetes . Nonpharmacologic Treatment 
Diet and lifestyle approaches, including weight loss, exercise, 
and dietary adjustment, may prevent and control of hypertension 
(DASH) therapy. 
Combining nonpharmacologic and pharmacologic therapy 
controls BP better than nonpharmacologic treatment alone .  
Regular moderate aerobic excercises  of moderate intensityf 
or at least 30-45 minutes per day for atleast 5 days in a week. 
Restriction of salt in diet,avoiding dairy fats,stopping 
smoking  all help in reducing hypertension. 
 28 
Taking plenty of fresh fruits and vegetables,nuts like 
walnuts,almonds,pistachio which are rich in pottasium are good for 
the heart. 
Table below  summarizes recommendations for non-
pharmacologic therapy. 
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RECOMMENDATIONS FOR NON PHARMACOLOGIC 
THERAPY 
 
Drugs Used in Hypertension 
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Contd -Drugs Used in Hypertension 
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INDICATIONS AND CONTRAINDICATIONS FOR THE 
MAJOR CLASSES OF ANTIHYPERTENSIVE DRUGS 
 
DYSLIPIDEMIA 
The relation of blood cholesterol with the risk of coronary 
artery disease (CAD) has been evaluated in many prospective 
observational studies and combined together in two large 
collaborative individual patient data meta analyses which have 
published relevant data. 
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1) The Prospective Studies Collaboration (PSC), which contains 
studies mainly from Europe and North America ,some from 
participants from studies conducted in China or Japan .  
2) The Asia Pacific Cohort Studies Collaboration (APCSC), 
contains cohort studies on asian population.  
These observational studies shows positive relation between 
normal levels of total cholesterol (a surrogate marker for LDL 
cholesterol) and the  increased risk of CAD. 
CHOLESTEROL SYNTHESIS AND REGULATION 
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STEPS IN CHOLESTEROL SYNTHESIS AND REGULATION  
Step-1 
1) HMG CoA is formed by 3 molecules of acetyl CoA. 
2) HMG CoA is  produced in the mitochondria matrix 
Step-2 
1) HMG CoA reductase conversion of HMG CoA to mevalonate  
2) Statin drug such as atorvastatin act as competitive inhibitors 
with mevalonate for binding to HMG CoA reductase. 
Step-3 
1) farnesyl pyrophosphate (FPP) is formed from mevalonate and 
intermediate in cholesterol synthesis. 
2) Squalene is formed by several condensation reactions 
involving isopentenyl pyrophosphate. 
Step-4 
a. Conversion of squalene to cholesterol requires NADPH. 
Step-5 
a. Cholesterol is excreted in bile and also used to synthesize 
bile acids and salts. 
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THE LIPOPROTEINS 
Introduction 
Michel Macheboeuf is known as the father of plasma 
lipoproteins. He was a French physician and scientist.  
Physiology of lipoprotiens 
Lipids are transported in  the plasma on lipoproteins, they are 
classified by their density and electrophoretic mobility into four 
major groups.  
1) Chylomicrons.  
2) Very low density lipoproteins(VLDL).  
3) Low density  lipoproteins (LDL).  
4) High density lipoproteins (HDL).  
Chylomicrons and VLDL primarily transport triglycerides 
(TG) while LDL and HDL are cholesterol rich lipoproteins.  
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Lipoprotein Classification and Properties 
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Cholesterol and triglycerides are required by peripheral 
tissues for multiple   metabolic functions, involving the 
maintenance of cell membranes, synthesis of steroid hormones and 
bile acid, and energy utilization. These lipids are carried on a range 
of lipoproteins in the systemic circulation. 
 
Transport and Fate of Dietary Fats 
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One of the functions of LDL particles is the transport of 
cholesterol into the arterial wall where it is retained by arterial 
proteoglycans. Macrophages are attracted to these sites and 
function to engulf the LDL particles. The process of engulfing LDL 
particles by macrophages initiates plaque formation in the arterial 
wall. 
 Increased levels of plaque formation are linked to 
atherosclerosis. Over time, plaques become vulnerable to rupturing, 
which, in turn, activates blood clotting and leads to arterial  
stenosis. 
 
Metabolism of lipoproteins of hepatic origin 
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Fatty acids are transported in the blood bound to albumin. 
Nonabsorbable plant sterols found in soybeans reduce the 
absorption of cholesterol, by competing with cholesterol for 
esterification with fatty acids.  
LIPOPROTEIN STRUCTURE 
The basic lipoprotein structure typically includes a core of 
esterified cholesterol and triglyceride, surrounded by a surface 
bilayer of phospholipid, unesterified or free cholesterol, and a 
range of proteins (termed “apolipoproteins”). 
 
Lipoprotein structure 
 39 
 
SECONDARY CAUSES OF HYPERCHOLESTEROLEMIA 
1) Hypothyroidism    
2) Obstructive liver disease    
3) Nephrotic syndrome   
4) Increasing consumption of saturated fat 
SECONDARY CAUSES OF HYPERTRIGLYCERIDEMIA 
Diabetes mellitus, Chronic renal failure, Obesity, Nephrotic 
syndrome ,   
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Cushing syndrome, Lipodystrophy , HIV, Cigarette smoking , 
Excess alcohol consumption , High-carbohydrate diets 
 
MEDICATIONS ASSOCIATED WITH DYSLIPIDEMIA 
RECOMMENDED LIPID GOALS 
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LIPOPROTEINS AND CARDIOVASCULAR BENEFIT-RISK 
Plasma lipoproteins are complex biological structures which 
are comprised of  
apolipoproteins A-1 (in high-density lipoprotein, HDL) or B-
100 in the small dense particles in low density lipoproteins (LDL) 
and cholesterol esters. Patients with metabolic disorders, such as 
the metabolic syndrome and type 2 diabetes, also have lipoprotein 
abnormalities such as elevated triglycerides and low levels of HDL 
cholesterol (HDL-C).  
Elevated levels of HDL-C are linked with reduced CV 
events.The classical role of HDL is reverse cholesterol transport in 
which lipids taken from macrophage foam cells transfer their 
cholesterol content to HDL particles for transport to liver  for 
degradation of cholesterol in hepatocytes, the products of which are 
excreted in the bile.  
Epidemiological studies have shown that decreased levels of 
HDL-C is a risk factor for CAD.  < 2% decrease in HDL-C is 
associated with a 3–5% increase in cardiovascular disease, while 
each 2 % reduction in HDL-C correlates with a 10 % increase in 
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deaths from coronary artery disease, which is independent of the 
LDL-C level. 
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THERAPIES AVAILABLE FOR DYSLIPIDEMIA 
ISCHAEMIC HEART DISEASE (IHD)  
DEFINITION  
The World Health Organisation has defined ischaemic heart 
disease (IHD) as myocardial dysfunction due to imbalance between 
coronary blood flow and myocardial requirements. 
The most common cause of IHD is coronary artery disease 
mainly due to atherosclerosis. However, imbalance between the 
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supply and demand can be caused by other conditions  as well, like 
hypertrophic cardiomyopathy ,aortic valve disease, coronary artery 
spasm and coronary artery involvement in various collagen 
disorders. 
Coronary artery disease(CAD) is the narrowing of the 
coronary arteries as a result of a plaque  which is composed of the 
following: 
 Lipids (cholesterol esters and crystals), which are deposited 
at the center of the plaque also  accumulate within 
macrophages. 
 Intimal smooth muscle cells,which proliferate. 
 A fibrous cap made of connective tissue. 
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COMPLEXITY OF EVENTS THAT DRIVE THE 
ATHEROSCLEROTIC PROCESS 
Coronary artery disease (CAD) is mainly due to coronary 
atherosclerosis causing various clinical syndromes of CAD .The 
clinical manifestations of CAD are a spectrum that includes various 
forms of ACS including  
 Angina pectoris  
 UA 
 NSTEMI  
 STEMI 
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Spectrum and definition of the acute coronary syndrome 
Acute coronary syndromes result from complicated 
interactions between the coronary circulation and the myocardium, 
mainly due to coronary artery atherosclerosis as the main reason for 
disease. 
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Acute coronary syndromes 
 48 
 
Differential diagnoses acute chest pain 
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Risk factors for CAD can be classified into 3 classes 
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Representative biomarkers involved in the process of 
Atherosclerosis 
NEW RISK FACTORS FOR IHD 
 Prothrombin fragment 1 & 2. 
 Factors V, VII, and VIII. 
 D-Dimer. 
 Lipoprotein(a). 
 Small dense LDL. 
 HDL subtypes. 
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 Apolipoproteins A1 and B. 
 Oxidized LDL. 
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PATHOPHYSIOLOGY OF MECHANISM OF ISCHEMIA 
 Myocardial oxygen supply is reduced in conditions like 
1) Coronary artery disease due to atherosclerotic lesion occluding the 
vessel, plaque, rupture, subintimal haemorrhage, platelet 
aggregates, thrombosis, and spasm on a pre existing atheromatous 
lesion. 
2) Arterial spasm occurring de novo. 
3) Coronary artery embolism, as in patients with mitral valve 
disease with atrial fibrillation, or myxoma of left atrium.  
4) Paroxysmal supraventricular tachycardia which leads to 
shortening of diastole 
5) Coronary artery disease in collagen disorders like 
disseminated lupus erythematosus, polyarteritis nodosa, 
aortoarteritis, Kawasaki disease. 
6) Anomalous origin of left coronary artery from the pulmonary 
artery. 
7) Anemia, CO poisoning. 
FOUR  important pathologic processes cause an acute athero 
thrombotic incident : 
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Atherosclerotic plaque rupture that disrupts the balance of 
thrombosis and fibrinolysis, causing the formation of a 
superimposed non occlusive thrombus.  
 
1) Arterial remodeling during atherogenesis. 
2) Fibrous cap rupture of the plaque leading to thrombosis.  
3) The clot disrupts endogenous fibrinolytic mechanisms 
4) Thrombin causes fibrosis  and  a fibroproliferative response 
that causes artery stenosis. 
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ACUTE MYOCARDIAL INFARCTION /STEMI 
Myocardial infarction is defined as  myocardial necrosis 
resulting from prolonged ischemia from a pathologic process.  
A recent working group from the ACC/ESC established the 
criteria for diagnosis of AMI as a rapid rise or fall in a cardiac 
necrosis biomarker, ideally troponin plus one additional factor:  
1) Symptoms of ischemia. 
2) ECG changes consistent with ischemia (ST deviation from J 
point) ≥1 mm or a new LBBB. 
3) New pathological Q waves (≥0.04 mm wide and/or 1/3 the 
height of the QRS). 
4) Imaging evidence of a new wall motion abnormality or a new 
loss of viability in an area of myocardium. 
CLINICAL PRESENTATION 
Patients with ACS typically present with angina  at rest or 
with minimal exertion, though 50% of all MIs may be clinically 
silent and not recognized by the patient. 
 Angina is a vague not localized chest or arm discomfort, 
often occurring along  with physical exertion or  cold climate or 
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during emotional stress, it is usually relieved within 5–10 min by  
taking rest or nitroglycerin.  
Evaluation of chest pain: A 12 lead ECG should be taken 
immediately. 
The presence of ST segment deviation or T wave inversions 
in 2 contiguous leads  suggestive of  ischemia  or infarction be 
further tested  with cardiac troponin  which is highly specific(80%) 
and sensitive(90%) in detecting myocardial cell necrosis.  
EXTENSIVE INFERIOR WALL STEMI (ACUTE) 
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Cardiac Troponin elevation can be detected in the blood as 
early as two to four hours after onset of symptoms and detectable 
7–14 days following an ACS. 
Diagnosis and Treatment in STEMI: Initial diagnostic measures 
1) Continuous serial ECGs; Pulse oximetry (SaO2), BP, PR.  
2) Clinical history (Thrombolysis contraindications).  
3) A 12-lead ECG  and Chest X-ray.  
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ELEVATION OF CARDIAC TROPONINS  BECAUSE OF 
MYOCARDIAL INJURY 
Novel biomarkers in ACS 
 Copeptin: It is the  fragment of vasopressin which is stable,  
and can rapidly rule out of MI if  it is measured together with 
a  hscTn, assay . There is evidence indicating that following a 
small infarct, copeptin is rapidly released from the pituitary 
gland and appears rapidly in the blood in patients with an 
evolving MI, while cTn is still negative . Copeptin 
concentrations decline fast to normal as cTn levels rise above 
the 99th percentile. Copeptin levels do not increase in 
patients with UA. 
 MR-proatrial natriuretic peptide:  ANP is derived from the 
cleavage of its precursor proatrial natriuretic peptide 
(proANP) . More recently, there is some evidence for a 
prognostic role for ANP in different settings of ACS. 
 Heart fatty acid-binding protein (h-FABP) 
 Ischemia-modified albumin (IMA) 
 MR-proadrenomedullin. 
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General treatment in ACS 
 
 Supplemental Oxygen 4–7 L per min. 
 NTG 0.4 mg sublingual every 5 min (caution in right 
ventricular infarctions because of hypotension) 
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 Analgesics like Morphine (2–4 mg IV)  or pethidine as 
needed. 
SPECIFIC TREATMENT IN STEMI  
Reperfusion therapy  
Either Primary PTCA or Thrombolysis 
 
 
Fibrinolytic therapy for acute myocardial infarction 
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2. ANTIPLATELET THERAPY 
 
 63 
MECHANISM OF ACTION OF VARIOUS ANTIPLATELET 
DRUGS 
 
GPIIB/IIIA INHIBITORS 
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UNFRACTIONATED HEPARIN 
 
ENOXAPARIN DOSAGE GUIDELINES 
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CONTRAINDICATIONS AND CAUTIONS FOR 
FIBRINOLYSIS IN STEMI 
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Difference between PTCA and CABG 
COMPLICATIONS OF ACUTE MI 
Immediate complications(within hours) 
 Complete heart block. 
 Hypotension. 
 Right ventricular infarction. 
 Cardiogenic shock Where hypotension (systolic BP <90 
mmHg) Pulmonary congestion and pulmonary oedema .  
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Ventricular fibrillation 
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KILLIP CLASSIFICATION OF CARDIOGENIC SHOCK 
Early complications(within days) 
 New murmur. 
 Mitral regurgitation due to papillary muscle rupture.  
 
Complete rupture of the posterior papillary muscle Ventricular septal 
rupture 
 
Rupture of myocardial free wall 
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 Pericarditis can happen 35% of patients with STEMI within 
the 7 days.  
 Late complications (several weeks) 
 Dressler syndrome: A form of post infarction pericarditis, 
occurs 7 days to 7 weeks after the acute event characterised 
by pleuritic chest pain,fever, elevated ESR.  
 Left ventricular aneurysm: Develops most commonly after 
a large transmural anterior myocardial infarction. 
 
Long-term secondary prevention therapy 
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Unstable angina (UA) and non-ST elevation myocardial 
infarction (NSTEMI) Both UA  and NSTEMI are continuity of the 
acute coronary syndrome (ACS) spectrum which includes STEMI.  
Unstable angina is characterized by following features 
 Angina occurring at rest  
 Recent onset   
 
Patients with ACS are risk stratified on the basis of certain 
criteria, to assess which of them would benefit from early invasive 
therapy PCI (percutaneous coronary intervention) and who will be 
managed conservatively. Many risk profile models like TIMI , 
GRACE have been proposed for triage assessment.  
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The TIMI risk score is determined by seven variables, each of 
which is assigned one point. Patients with scores of five or more 
have been shown to have a higher risk of adverse events and a 
higher mortality and these patients should be advised early 
coronary angiography and revascularisation. 
 
TIMI Risk Score 
 
General overview of the treatment of UA/NSTEMI-ACS 1 
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MATERIALS AND METHODS 
SETTING  
This study was conducted at the Hypertension clinic, Rajiv 
Gandhi Government General Hospital and Madras Medical College.  
ETHICAL COMMITTEE APPROVAL  
Obtained.  
STUDY DURATION  
This study was conducted over a period of six months.  
STUDY POPULATION  
Patients coming to hypertension clinic for hypertension 
management. 
SAMPLE SIZE  
50 patients 
TYPE OF STUDY  
Cross sectional,Observational study  
INCLUSION CRITERIA  
 Adult hypertensives with B.P controlled or uncontrolled with 
anti hypertensive treatment.  
 Duration  of hypertension since diagnosis ≥6 months  
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EXCLUSION CRITERIA 
 Patients with fever. 
 Patients with acute or chronic inflammatory diseases. 
 CAD,CVA,PVD,CKD. 
 Acute or chronic infectious diseases. 
 Diabetes,IBD,TB,COPD,Connective tissue diseases. 
 h/o hypothyroidism. 
 On treatment with NSAIDS, steroids,aspirin and statins. 
DATA COLLECTION AND METHODS 
Informed consent was obtained from all the patients 
participating in the study.  
 Patients were subjected to detailed history taken according to 
a questionnaire and clinical examination.  
 CBC . 
 RFT 
 LFT. 
 FBS,PPBS 
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 Fasting lipid profile. 
 Urine analysis. 
 Standard 12 lead ECG . 
 Body mass index. 
 Echocardiography. 
 HsCRP done in every case. 
Patients were classified according to JNC 7 
staging,classification of HTN. 
B.P was measured in right upper limb in sitting posture with a 
digital sphygmomanometer. 
PROCEDURE / INVESTIGATION DETAILS 
Blood samples are collected from the antecubital vein using 
2cc syringe transferred to a test tube and analyzed by standard 
proceedures.     
 HsCRP-levels measured by fully automated nephelometry 
 Fasting Lipid profile measured by Photometry.  
 Total cholesterol measured by CHOD POD assay.  
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 HDL-C measured by Enzyme selective protection assay.  
 LDL –C measured by Homogenous enzymatic colorimetrics 
assay. 
 Triglycerides measured by Enzymatic colorimetric method.  
All the data  collected was entered in the Proforma 
[enclosed]. 
STATISTICS AND ANALYSIS       
Data was analyzed using Software: SPSS, Version 20.0  
 If the p value is 0.000 to 0.010 then it implies significant at 1 
level (highly significant ) 
 If the p value is 0.011to 0.050 then it implies significant at 5 
level. 
 If the p value is 0.051 to 1.000 then it implies not significant 
at 5 level (not significant) 
 Association between 2 variable categories was made using  
the chi square test. 
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OBSERVATION AND RESULTS 
SEX DISTRIBUTION IN STUDY GROUP 
Gender Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
Male 30 60.0 60.0 60.0 
Female 20 40.0 40.0 100.0 
Total 50 100.0 100.0  
 
 
No of patients study group were total 50 out of which 60% 
male and 40%  females. 
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AGE DISTRIBUTION AMONG STUDIED  
Age in years Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
Below 50 10 20.0 20.0 20.0 
51-60 25 50.0 50.0 70.0 
61-70 12 24.0 24.0 94.0 
Above 70 3 6.0 6.0 100.0 
Total 50 100.0 100.0  
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HYPERTENSION IN STUDIED GROUP 
HTN Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Yes 50 100.0 100.0 100.0 
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DISTRIBUTION OF BLOOD PRESSURE IN STUDY GROUP , 
MMHG 
BP mmHG Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
< 130/80 25 50.0 50.0 50.0 
131/81 – 
140/90 
13 26.0 26.0 76.0 
141/91- 
159/100 
6 12.0 12.0 88.0 
> 160/100 6 12.0 12.0 100.0 
Total 50 100.0 100.0  
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NUMBER OF ANTI HTN DRUGS  IN STUDY GROUP  
Number of 
Drugs 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
1 2 4.0 4.0 4.0 
2 27 54.0 54.0 58.0 
3 18 36.0 36.0 94.0 
4 3 6.0 6.0 100.0 
Total 50 100.0 100.0  
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DURATION OF BP IN STUDIED GROUP 
Duration of 
BP in years 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
< 5 26 52.0 52.0 52.0 
6-10 16 32.0 32.0 84.0 
> 10 8 16.0 16.0 100.0 
Total 50 100.0 100.0  
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HS-CRP  LEVELS WITH RISK CATAGORIES MG/L 
Hs-CRP  
mg/L 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
< 1 11 22.0 22.0 22.0 
1-3 31 62.0 62.0 84.0 
> 3 8 16.0 16.0 100.0 
Total 50 100.0 100.0  
 
 Hs-CRP  mg/L 
Chi-Square(a) 18.760 
df 2 
Asymp. Sig. .000 
p value is  < 0.001 is highly significant 
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BP DISTRIBUTION AMONG GENDERS IN STUDY GROUP 
BP  mmHg * Sex  
Sex 
Total 
Male Female 
Number 
< 130/80 
Count 14 11 25 
% within BP  
mmHg 
56.0% 44.0% 100.0% 
% within Sex 46.7% 55.0% 50.0% 
 
131/81 - 
140/90 
Count 8 5 13 
% within BP  
mmHg 
61.5% 38.5% 100.0% 
% within Sex 26.7% 25.0% 26.0% 
 
141/91-
159/100 
Count 4 2 6 
% within BP  
mmHg 
66.7% 33.3% 100.0% 
% within Sex 13.3% 10.0% 12.0% 
 
> 160/100 
Count 4 2 6 
% within BP  
mmHg 
66.7% 33.3% 100.0% 
% within 
Sex 
13.3% 10.0% 12.0%  
Total 
Count 30 20 50 
% within BP  
mmHg 
60.0% 40.0% 100.0% 
   
% within Sex 
100.0% 100.0% 100.0% 
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HS-CRP MG/L RISK STRATIFICATION AMONG GENDERS 
IN STUDY GROUP 
Hs-CRP  mg/L * 
Sex 
 
Sex 
Total 
Male Female 
Hs-CRP  
mg/L 
< 1 
Count 8 3 11 
% within Hs-CRP  
mg/L 
72.7% 27.3% 100.0% 
% within Sex 26.7% 15.0% 22.0% 
 
1-3 
Count 16 15 31 
% within Hs-CRP  
mg/L 
51.6% 48.4% 100.0% 
% within Sex 53.3% 75.0% 62.0% 
 
> 3 
Count 6 2 8 
% within Hs-CRP  
mg/L 
75.0% 25.0% 100.0% 
% within Sex 20.0% 10.0% 16.0% 
Total 
Count 30 20 50 
% within Hs-CRP  
mg/L 
60.0% 40.0% 100.0% 
% within Sex 100.0% 100.0% 100.0% 
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CORRELATION BETWEEN HS-CRP LEVELS AND 
DURATION OF HTN 
 
  
Hs-CRP  mg/L 
Total 
< 1 1-3 > 3 
Duration of 
BP years 
< 
5 
Count 8 15 3 26 
% within 
Duration of BP 
30.8% 57.7% 11.5% 100.0% 
% within Hs-
CRP  mg/L 
72.7% 48.4% 37.5% 52.0% 
6-
10 
Count 1 11 4 16 
% within 
Duration of BP 
6.3% 68.8% 25.0% 100.0% 
% within Hs-
CRP  mg/L 
9.1% 35.5% 50.0% 32.0% 
> 
10 
Count 2 5 1 8 
% within 
Duration of BP 
25.0% 62.5% 12.5% 100.0% 
% within Hs-
CRP  mg/L 
18.2% 16.1% 12.5% 16.0% 
Total 
Count 11 31 8 50 
% within 
Duration of BP 
22.0% 62.0% 16.0% 100.0% 
% within Hs-
CRP  mg/L 
100.0% 100.0% 100.0% 100.0% 
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BP (MEAN) IN GENDERS 
 
 Sex N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
SBP 
Male 30 136.20 16.529 3.018 
Female 20 133.60 15.446 3.454 
DBP 
Male 30 88.60 8.122 1.483 
Female 20 84.70 9.021 2.017 
 
132
132.5
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133.5
134
134.5
135
135.5
136
136.5
Male Female
SBP
SBP (mean) IN GENDERS
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DBP (MEAN) IN GENDERS 
 Sex N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
SBP Male 30 136.20 16.529 3.018 
Female 20 133.60 15.446 3.454 
DBP Male 30 88.60 8.122 1.483 
Female 20 84.70 9.021 2.017 
 
82
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84
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89
Male Female
DBP
DBP (MEAN) IN GENDERS
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HTN CLASSES AND LDL-C LEVELS 
  
LDL 
Total 
< 100 > 100 
BP  
mmHg 
< 130/80 
Count 20 5 25 
% within BP  
mmHg 
80.0% 20.0% 100.0% 
% within LDL 64.5% 26.3% 50.0% 
 
131/81 - 
140/90 
Count 5 8 13 
% within BP  
mmHg 
38.5% 61.5% 100.0% 
% within LDL 16.1% 42.1% 26.0% 
 
141/91-
159/100 
Count 4 2 6 
% within BP  
mmHg 
66.7% 33.3% 100.0% 
% within LDL 12.9% 10.5% 12.0% 
 
> 160/100 
Count 2 4 6 
% within BP  
mmHg 
33.3% 66.7% 100.0% 
% within 
LDL 
6.5% 21.1% 12.0%  
Total 
Count 31 19 50 
% within BP  
mmHg 
62.0% 38.0% 100.0% 
% within LDL 100.0% 100.0% 100.0% 
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HTN CLASSES AND TOTAL CHOLESTEROL LEVELS 
  
TC 
Total 
< 200 > 200 
BP  
mmHg 
< 130/80 
Count 23 2 25 
% within BP  
mmHg 
92.0% 8.0% 100.0% 
% within TC 57.5% 20.0% 50.0% 
131/81 - 
140/90 
Count 8 5 13 
% within BP  
mmHg 
61.5% 38.5% 100.0% 
% within TC 20.0% 50.0% 26.0% 
141/91-
159/100 
Count 4 2 6 
% within BP  
mmHg 
66.7% 33.3% 100.0% 
% within TC 10.0% 20.0% 12.0% 
> 160/100 
Count 5 1 6 
% within BP  
mmHg 
83.3% 16.7% 100.0% 
% within 
TC 
12.5% 10.0% 12.0%  
Total 
Count 40 10 50 
% within BP  
mmHg 
80.0% 20.0% 100.0% 
% within TC 100.0% 100.0% 100.0% 
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HTN CLASSES AND TRIGLYCERIDE LEVELS 
  
TGL 
Total 
< 150 > 150 
BP  
mmHg 
< 130/80 
Count 21 4 25 
% within BP  
mmHg 
84.0% 16.0% 100.0% 
% within TGL 52.5% 40.0% 50.0% 
131/81 - 
140/90 
Count 12 1 13 
% within BP  
mmHg 
92.3% 7.7% 100.0% 
% within TGL 30.0% 10.0% 26.0% 
141/91-
159/100 
Count 4 2 6 
% within BP  
mmHg 
66.7% 33.3% 100.0% 
% within TGL 10.0% 20.0% 12.0% 
> 160/100 
Count 3 3 6 
% within BP  
mmHg 
50.0% 50.0% 100.0% 
% within 
TGL 
7.5% 30.0% 12.0%  
Total 
Count 40 10 50 
% within BP  
mmHg 
80.0% 20.0% 100.0% 
% within TGL 100.0% 100.0% 100.0% 
BP  mmHg
> 160/100
141/91-159/100
131/81 - 140/90
< 130/80
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HSCRP CLASSES AND HDL-C LEVELS 
  
HDL 
Total 
< 40 > 40 
Hs-CRP  
mg/L 
< 
1 
Count 8 3 11 
% within Hs-CRP  
mg/L 
72.7% 27.3% 100.0% 
% within HDL 21.6% 23.1% 22.0% 
1-
3 
Count 21 10 31 
% within Hs-CRP  
mg/L 
67.7% 32.3% 100.0% 
% within HDL 56.8% 76.9% 62.0% 
> 
3 
Count 8 0 8 
% within Hs-CRP  
mg/L 
100.0% .0% 100.0% 
% within 
HDL 
21.6% .0% 16.0%  
Total 
Count 37 13 50 
% within Hs-CRP  
mg/L 
74.0% 26.0% 100.0% 
% within HDL 100.0% 100.0% 100.0% 
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HSCRP CLASSES AND LDL-C LEVELS 
  
LDL 
Total 
< 100 > 100 
Hs-CRP  
mg/L 
< 
1 
Count 7 4 11 
% within Hs-CRP  
mg/L 
63.6% 36.4% 100.0% 
% within LDL 22.6% 21.1% 22.0% 
1-
3 
Count 20 11 31 
% within Hs-CRP  
mg/L 
64.5% 35.5% 100.0% 
% within LDL 64.5% 57.9% 62.0% 
> 
3 
Count 4 4 8 
% within Hs-CRP  
mg/L 
50.0% 50.0% 100.0% 
% within 
LDL 
12.9% 21.1% 16.0%  
Total 
Count 31 19 50 
% within Hs-CRP  
mg/L 
62.0% 38.0% 100.0% 
% within LDL 100.0% 100.0% 100.0% 
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HSCRP CLASSES IN GENDERS 
  
Sex 
Total 
Male Female 
Hs-CRP  
mg/L 
< 
1 
Count 8 3 11 
% within Hs-CRP  
mg/L 
72.7% 27.3% 100.0% 
% within Sex 26.7% 15.0% 22.0% 
   
1-
3 
Count 16 15 31 
% within Hs-CRP  
mg/L 
51.6% 48.4% 100.0% 
% within Sex 53.3% 75.0% 62.0% 
   
> 
3 
Count 6 2 8 
% within Hs-CRP  
mg/L 
75.0% 25.0% 100.0% 
% within 
Sex 
20.0% 10.0% 16.0%  
Total 
Count 30 20 50 
% within Hs-CRP  
mg/L 
60.0% 40.0% 100.0% 
  % within Sex 100.0% 100.0% 100.0% 
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TOTAL CHOLESTEROL GENDER WISE 
  
Sex 
Total 
Male Female 
TC 
< 200 
Count 21 19 40 
% within TC 52.5% 47.5% 100.0% 
% within Sex 70.0% 95.0% 80.0% 
> 200 
Count 9 1 10 
% within TC 90.0% 10.0% 100.0% 
% within Sex 30.0% 5.0% 20.0%  
Total 
Count 30 20 50 
% within TC 60.0% 40.0% 100.0% 
% within Sex 100.0% 100.0% 100.0% 
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HDL- CHOLESTEROL GENDER WISE 
  
Sex 
Total 
Male Female 
HDL 
< 40 
Count 21 16 37 
% within HDL 56.8% 43.2% 100.0% 
% within Sex 70.0% 80.0% 74.0% 
 
> 40 
Count 9 4 13 
% within HDL 69.2% 30.8% 100.0% 
% within Sex 30.0% 20.0% 26.0%  
Total 
Count 30 20 50 
% within HDL 60.0% 40.0% 100.0% 
% within Sex 100.0% 100.0% 100.0% 
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LDL- CHOLESTEROL GENDER WISE 
  
Sex 
Total 
Male Female 
LDL 
< 100 
Count 19 12 31 
% within LDL 61.3% 38.7% 100.0% 
% within Sex 63.3% 60.0% 62.0% 
 
> 100 
Count 11 8 19 
% within LDL 57.9% 42.1% 100.0% 
% within Sex 36.7% 40.0% 38.0%  
Total 
Count 30 20 50 
% within LDL 60.0% 40.0% 100.0% 
  % within Sex 100.0% 100.0% 100.0% 
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RESULTS 
SEX DISTRIBUTION  
No of patients study group were total 50 out of which 60% 
male and 40%  females. 
AGE DISTRIBUTION  
The percent of patients with HTN in study group belonging to 
age below 50yrs was 20%, those belong to age 51-60yrs was 50%, 
those belongs to age 61-70 was 24% and above 70yrs of age 6%  
Significant number of patients belonged to 61-70yrs of age 
group in the study. 
HYPERTENSION IN STUDY GROUP 
100% of patients in study group had HTN which was either 
controlled or uncontrolled on Anti Hypertension treatment.  
DISTRIBUTION OF BP IN MMHG IN STUDY GROUP 
BP < 130/180 mmHg : 55%. 
BP 131/81 – 140/90 mmHg : 26% 
BP   141/91-159/99 mmHg : 12% 
BP    160/100 mmHg : 12% 
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Significant number of patients had BP <130/80  mmHg 
PATIENTS WITH NO. OF ANTI HYPERTENSION DRUGS IN 
STUDY GROUP 
a.Patients with 1 drug were 4% 
b.Patients with 2 drugs were 54% 
c.Patients with 3 drugs were 36% 
d.Patient with 4 drugs were 6% 
Significant no of patients on antihypertension treatment was 
on 2 drugs at the time of study. 
DURATION OF HTN AND WITH DURATION OF HTN  
>6 MONTHS 
Patients with duration of BP 
<5yrs were -52% 
6-10yrs were -32% 
>10yrs were -16% 
Significant no. of patients had HTN of duration more than <5 
yrs. 
HS-CRP  LEVELS WITH RISK CATEGORIES  IN MG/L 
Patients with HSCRP <1mg LOW risk category  was  22% 
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HRCP >1-3 MODERATE  risk category   was    62% 
HRCP >3mg HIGH  risk category was 8% 
 Highly Significant (p value is 0.001) no of patient had 
HsCRP levels of >1-3mg/L belonging to moderate risk category. 
BP DISTRIBUTION AMONG GENDERS IN STUDY GROUP 
1) Bp <130/80 mmhg no.of males was 14(56%) and no.of 
females was 11(44%). 
2) Bp  131/81-140/90 mmhg no.of males was 8 (61.5%) and 
no.of females was 5(38.5%). 
3) Bp 141/91-159/100 mmhg no.of males was 4 (66.7%) and 
no.of females was 2 (33.3%). 
4) Bp > 160/100 mmhg no.of males was 4 (66.7%) and no.of 
females was 2 (33.3%). 
HS-CRP MG/L RISK STRATIFICATION AMONG GENDERS 
IN STUDY GROUP 
1) Male patients with  
HsCRP <1mg    LOW risk category  was 8 (72.7%) 
HsCRP  >1-3 mg  MODERATE  risk category was 16 (51.6%) 
HsCRP >3 mg    HIGH  risk category was 6 (75.0%) 
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2) Female Patients with  
 HsCRP <1mg     LOW risk category was 3 (27.3%) 
 HsCRP >1-3     MODERATE  risk category was15 (48.4%) 
 HsCRP >3mg     HIGH  risk category was 2 (25.0%) 
CORRELATION BETWEEN HS-CRP LEVELS AND 
DURATION OF HTN 
1) With Duration of BP < 5 years with HsCRP <1mg  no.of 
patients was 8(30.8%), with HsCRP >1-3  no.of patients was 
15(57.7%), with HsCRP >3  no.of patients was 3(11.5%) 
2) With Duration of BP 6-10 years with HsCRP <1mg  no.of 
patients was 1 (6.3%), with HsCRP >1-3  no.of patients was 
1(68.8%), with HsCRP >3  no.of patients was 4(25%) 
3) With Duration of BP > 10 years with HsCRP <1mg  no.of 
patients was 2(25%), with HsCRP >1-3  no.of patients was 
5(62.5%), with HsCRP >3  no.of patients was 1(12.5%). 
Mean SYSTOLIC and DIASTOLIC BP in males and female 
subjects 
Mean SBP in male subjects was 136 mmhg. 
Mean SBP in female subjects was 133mmhg. 
Mean DBP in female subjects was 84 mmhg. 
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DISCUSSION 
HsCRP levels can be used as a marker of latent 
atherosclerosis and cardiovascular risk. 50% of all ACS occur in 
persons who do not have dyslipidemia. Studies have shown that that 
the combined evaluation of CRP levels  and lipid profile may 
improve risk stratification and also identify asymptomatic 
individuals at higher risk of cardiovascular events 
 AHA and CDC recommended the utility of testing of CRP 
levels as an adjunct to CV risk assessment. CRP was recommended 
over the other inflammatory biomarkers whichare available because 
it  is advanced and validated clinical assay and  has a larger 
supporting data for its accuracy and validity.  
Risk categorization by HsCRP levels interpretation 
guidelines: Less than 1mg/L, lower risk; between 1–3 mg/L, 
intermediate risk and more than 3 mg/L, higher risk. Testing of 
CRP as a optional use was recommended for those at intermediate 
risk (8–15% absolute 10 year risk of CAD events) by the 
Framingham Risk Score. 
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HsCRP adds prognostic value at all levels of LDL-
C,Framingham coronary risk score, and BP levels,  also in those 
individuals with and without subclinical atherosclerosis.In clinical 
settings, HsCRP should be used in combination with lipid profile 
evaluation.  
Advanced knowledge of cardiovascular risks can lead to 
better lifestyle and pharmacological interventions targeted to 
prevent future CV events.  
In this observational study subjects with hypertension were 
categorized according to JNC7 classification of hypertension. 
Subjects grouped into duration of hypertension were 
compared  with HsCRP levels and subjects categorized into 3 risk 
categories of <1mg/L,1-3mg/L and >3mg/L. 
There was significant  no.of patients in the moderate risk 
category with HsCRP levels between 1-3mg/L ( p value is < 0.001) 
but no statistical significance observed when HsCRP levels were 
correlated with  the duration of hypertension or with levels of  
Total cholesterol, LDL-C and HDL-C.  
 103 
CONCLUSION 
In summary ,this study observed that HsCRP levels of >1-
3mg/L were elevated  significantly in subjects with hypertension (p 
value is < 0.001)  irrespective of  their BP levels and duration of 
hypertension. 
There was no statistical significance  and correlation between 
levels of HsCRP  and hypertension with levels of LDL-C or HDL-C 
in the study group. 
CLINICAL IMPORTANCE 
HsCRP levels can be evaluated in hypertensive individuals who do 
not have symptomatic CAD irrespective of abnormal Lipid profile and 
can be provided with primary prevention to prevent future cardiovascular 
events. 
LIMITATIONS OF STUDY 
The main limitation in this study was the small size of study group. 
Further follow up study of patients in moderate to high risk 
category with elevated levels of HsCRP is needed. 
A larger study group with evaluation of the complete clinical 
profile of persons with hypertension and also comparing the type of 
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antihypertensive with the lipid profile and HsCRP levels could have  
provided with better  risk stratification,leading to providing better 
primary prevention of CAD. 
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 STUDY ON HIGH SENSITIVITY C REACTIVE PROTIEN (hsCRP) 
LEVELS & CORRELATION WITH LIPID PROFILE IN 
HYPERTENSION 
                                     
PROFORMA 
 
Name : 
Age/Sex : Weight : 
IP/OP No : Diagnosis : 
Patient ID No : Duration : 
Patient characteristics Medications 
 Systemic hypertension   Calcium channel blockers 
 Diabetes   Statins 
 Smoking  Beta blockers 
 Diet  ACE inhibitors 
 Alcoholism  Others 
Vascular complications 
 Coronary events  Cerebrovascular events 
 Peripheral vascular diseases  
 
Symptoms: 
Chest pain:                                         Dyspnoea:                            
Cough:                                        Palpitations: 
Sweating:    Presyncope/Syncope: 
Swelling Of Legs:                                  Easy Fatigability: 
Facial Puffiness:                                    Decreased Urine Output: 
Others: 
 Past history: 
Diabetes mellitus:       Coronary artery disease:       
Recent infection:       Recent hospitalization: 
Connective tissue disorders:       Other comorbid illnesses: 
Hypertension:                                                    Kidney disease:                                
Stroke:                              Hematological illness: 
Heart failure:                              Liver disease:                                                                         
Tuberculosis:                                                          Recent surgery/trauma: 
COPD:                                                                    Br.Asthma: 
Drug history: 
 
Family history: 
Personal history: 
 Diet 
 Sleep  
 Bowel/bladder 
 Substance abuse 
Menstrual history: 
 
VITALS:   
Pulse:                                   JVP:                                                           
Respiratory Rate:                       Blood Pressure:                              
General examination: 
Weight:                          Height: 
Body mass index:   Icterus: 
Pallor:                     Lymphadenopathy: 
Cyanosis                                        Pedal edema: 
Clubbing:  
 
Systemic examination: 
CVS: 
                Apical impulse 
                Heart sounds(S1,S2,S3,S4) 
                Murmurs 
                Basal crepitations 
        
RS: 
 
 
ABDOMEN: 
 
 
CNS: 
 
 
Investigations: 
COMPLETE BLOOD COUNT 
Total leucocyte count            cells/cu.mm 
Neutrophils              % 
Lymphocytes             % 
Eosinophils              % 
Basophils              % 
Monocytes              % 
Hemoglobin              g/dl 
Hematocrit             % 
ESR            mm/1 hour 
RBC count            Million/cu.mm 
Platelet count            Cells/cu.mm 
RFT LFT 
Glucose(F)  mg/dl Total bilirubin  mg/dl 
Urea  mg/dl Direct bilirubin  mg/dl 
Creatinine  mg/dl SGOT  U/l 
Na+  mEq/l SGPT  U/l 
K+  mEq/l ALP  U/l 
  Total protein  g/dl 
  Albumin  g/dl 
hsCRP  
 
                                                 Urine analysis:            
FASTING LIPID PROFILE 
Total cholesterol    mg/dl 
Triglycerides    mg/dl 
LDL    mg/dl 
HDL    mg/dl 
VLDL    mg/dl 
ECG:  
 
 
Echocardiography: Regional wall motion abnormality: 
                      Ejection fraction:                 
INFORMATION SHEET 
We are conducting a study on “HIGH SENSITIVITY C REACTIVE 
PROTIEN (HSCRP) LEVELS & CORRELATION WITH LIPID 
PROFILE IN HYPERTENSION” among patients attending Rajiv Gandhi 
Government General Hospital, Chennai and for that your specimen may be 
valuable to us. 
The purpose of this study is to evaluate HIGH SENSITIVITY C REACTIVE 
PROTIEN (hsCRP) LEVELS & CORRELATION WITH LIPID 
PROFILE IN HYPERTENSION” to identify and risk stratify patients at risk 
for cardio vascular events & primary prevention of coronary artery disease.. 
We are selecting certain cases and if you are found eligible, we may be 
using your blood samples to do special studies which in any way do not affect 
your final report or management. 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid in 
the management or treatment. 
 
Signature of Investigator 
 
 
Date : 
Place :
Signature of Participant
  
 
PATIENT CONSENT FORM 
Study Detail : “HIGH SENSITIVITY C REACTIVE PROTIEN 
(hsCRP) LEVELS & CORRELATION WITH LIPID 
PROFILE IN HYPERTENSION” 
 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the 
above study. I have the opportunity to ask question and all my 
questions and doubts have been answered to my complete 
satisfaction.  
b) I understand that my participation in the study is voluntary and that I 
am free to withdraw at any time without giving reason, without my 
legal rights being affected.  
c) I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities 
will not need my permission to look at my health records, both in 
respect of current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study I agree 
to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any 
data or results that arise from this study.  
  
d) I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperate with the 
study team and to immediately inform the study staff if I suffer from 
any deterioration in my health or well being or any unexpected or 
unusual symptoms.  
e) I hereby consent to participate in this study.  
f) I hereby give permission to undergo complete clinical examination 
and hematological tests and ECHO Cardiography.   
Signature/thumb impression                                  Signature of Investigator 
 
 
 
Patient’s Name and Address                                 Study Investigator’s Name:                                                                                                                               
                                                   Dr. DEVANAND KUMAR.G 
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S.No Age Sex HTN SBP DBP Drugs Duration of BP Hs_CRP TC HDL LDL TGL
1 48 1 1 150 90 AC 2 0.39 141 34 74 137
2 53 1 1 140 90 BC 3 1.51 205 53 116 99
3 45 2 1 160 90 ABC 5 1.60 196 36 110 168
4 52 1 1 140 96 AC 1 2.13 140 32 96 90
5 58 2 1 120 76 BC 7 1.73 174 36 90 164
6 56 1 1 150 100 BCD 7 2.45 219 36 102 190
7 49 2 1 110 70 AC 3 1.72 186 48 124 148
8 62 1 1 140 90 ABC 6 3.01 114 38 70 54
9 56 2 1 150 90 ABC 10 2.40 194 32 56 130
10 68 1 1 160 100 BCD 18 3.10 136 30 72 80
11 50 2 1 170 100 A 1 6.00 198 35 110 181
12 54 1 1 160 90 BC 5 0.76 156 33 106 112
13 52 1 1 150 100 ACD 5 1.80 210 46 106 96
14 69 2 1 140 90 ACD 10 1.35 156 34 97 100
15 68 1 1 120 86 BC 8 3.05 185 33 96 109
16 46 1 1 110 80 BC 3 1.18 181 36 96 259
17 55 2 1 120 80 A 3 1.62 178 32 110 93
18 62 1 1 140 100 CD 9 7.09 220 30 130 150
19 76 2 1 136 90 ABCD 21 2.08 251 33 104 134
20 52 1 1 170 100 ARCD 1 1.90 183 45 94 174
21 54 1 1 100 80 BC 3 1.42 148 32 95 132
22 57 2 1 130 90 BC 6 0.89 156 38 100 160
23 60 2 1 130 80 ABC 7 1.90 170 35 82 88
24 70 1 1 130 80 AC 21 0.16 223 57 129 159
25 56 2 1 140 90 ACD 3 0.42 125 44 72 76
26 75 1 1 140 90 BC 19 1.20 205 44 118 161
27 48 1 1 120 84 BC 1 4.20 130 31 75 71
28 66 1 1 110 76 ABCD 13 2.00 174 62 82 74
29 58 2 1 130 80 ABC 7 2.35 146 32 92 102
MASTER CHART
S.No Age Sex HTN SBP DBP Drugs Duration of BP Hs_CRP TC HDL LDL TGL
30 67 1 1 140 80 ABC 19 0.65 194 46 106 92
31 54 1 1 130 80 AD 4 0.99 186 32 96 98
32 52 2 1 130 80 BC 1 1.40 102 36 68 75
33 63 1 1 120 80 BC 9 2.12 140 52 74 82
34 48 1 1 160 100 ABC 2 3.05 208 31 108 64
35 59 2 1 140 100 AB 6 4.02 176 36 116 68
36 53 1 1 156 100 ACD 6 1.99 138 32 82 164
37 50 2 1 110 80 AD 4 2.00 154 32 84 71
38 72 2 1 146 96 ACD 16 2.80 168 30 48 98
39 58 1 1 120 84 AB 1 1.64 162 46 84 76
40 65 2 1 130 72 ABC 3 0.56 132 30 86 76
41 70 2 1 120 84 AD 20 1.78 148 34 88 108
42 55 1 1 130 96 ACD 6 1.80 138 36 76 78
43 60 1 1 130 90 AC 5 2.40 224 36 78 140
44 62 2 1 140 86 ABC 9 2.30 180 52 106 92
45 58 1 1 130 80 AC 1 1.26 150 32 106 72
46 56 2 1 120 70 AD 3 1.14 194 42 106 92
47 60 1 1 130 86 AB 2 0.68 154 36 66 106
48 48 1 1 140 90 AD 1 0.98 206 32 110 128
49 48 1 1 130 80 ABC 8 1.21 132 32 82 68
50 55 1 1 140 80 AC 5 0.52 146 38 98 120
